Biocon Unit Secures USFDA Nod for Rare Disease Drug Generic

HEALTHCAREBIOTECH

Overview

Biocon Pharma has received U.S. Food and Drug Administration (USFDA) approval for its generic Everolimus tablets for oral suspension. The drug targets rare genetic conditions like tuberous sclerosis complex, bolstering Biocon's specialty drug portfolio in the lucrative U.S. market.

Biocon Ltd announced Monday that its subsidiary, Biocon Pharma Ltd, has secured approval from the U.S. Food and Drug Administration (USFDA) for its generic version of Everolimus tablets for oral suspension. This development marks a significant step for the Indian biopharmaceutical firm in expanding its presence in the U.S. market.

Regulatory Milestone

The approval was granted for an Abbreviated New Drug Application (ANDA) and covers the drug in 2 mg, 3 mg, and 5 mg strengths. This clearance is a testament to Biocon's capabilities in developing complex generic formulations.

Therapeutic Application

Everolimus tablets for oral suspension are indicated for specific rare genetic conditions. They are used to treat adult and pediatric patients aged one year and above with Tuberous Sclerosis Complex (TSC), a disorder characterized by non-cancerous tumors in various organs. The drug also aids in the adjunctive treatment of TSC-associated partial-onset seizures in patients aged two years and older.

Market Expansion

This USFDA clearance is expected to further strengthen Biocon's portfolio of vertically integrated drug products. The company has been strategically expanding its offerings in complex generics and biosimil segments, aiming to tap into high-value therapeutic areas and enhance its global revenue streams.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.